SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Geoffrey A. Lambert, Peter Boers, Alessandro S. Zagami, Triptan-Induced Sensitization of Trigeminovascular Sensation, Headache: The Journal of Head and Face Pain, 2015, 55, 1
  2. 2
    Jan Hoffmann, Simon Akerman, Peter J Goadsby, Efficacy and mechanism of anticonvulsant drugs in migraine, Expert Review of Clinical Pharmacology, 2014, 7, 2, 191

    CrossRef

  3. 3
    Irene Wood, Mónica Pickholz, Triptan partition in model membranes, Journal of Molecular Modeling, 2014, 20, 10

    CrossRef

  4. 4
    Peter J. Goadsby, All that is obvious is not clear: What is the origin of throbbing pain in migraine?, Pain, 2013, 154, 7, 970

    CrossRef

  5. 5
    Irene Wood, Mónica Pickholz, Concentration effects of sumatriptan on the properties of model membranes by molecular dynamics simulations, European Biophysics Journal, 2013, 42, 11-12, 833

    CrossRef

  6. 6
    Faisal Mohammad Amin, Mohammad Sohail Asghar, Anders Hougaard, Adam Espe Hansen, Vibeke Andrée Larsen, Patrick JH de Koning, Henrik BW Larsson, Jes Olesen, Messoud Ashina, Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study, The Lancet Neurology, 2013, 12, 5, 454

    CrossRef

  7. 7
    K. Ostermann, G. Juckel, P. Roser, Possible association of severe major depression with acute cessation of long-term excessive triptan use, Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 1
  8. 8
    Mark J. Stillman, Stewart Tepper, Deborah E. Tepper, Leslie Cho, QT Prolongation, Torsade de Pointes, Myocardial Ischemia From Coronary Vasospasm, and Headache Medications. Part 1: Review of Serotonergic Cardiac Adverse Events With a Triptan Case, Headache: The Journal of Head and Face Pain, 2013, 53, 1
  9. 9
    Nancy Sudak, Textbook of Natural Medicine, 2013,

    CrossRef

  10. 10
    S. Stuart, L. R. Griffiths, A possible role for mitochondrial dysfunction in migraine, Molecular Genetics and Genomics, 2012, 287, 11-12, 837

    CrossRef

  11. 11
    Min Kyung Chu, Dawn C. Buse, Marcelo E. Bigal, Daniel Serrano, Richard B. Lipton, Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study, Headache: The Journal of Head and Face Pain, 2012, 52, 2
  12. 12
    Hyo-Jin Jeong, Vanessa A Mitchell, Christopher W Vaughan, Role of 5-HT1 receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn, British Journal of Pharmacology, 2012, 165, 6
  13. 13
    Peer C. Tfelt-Hansen, Jes Olesen, The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials, The Journal of Headache and Pain, 2012, 13, 4, 271

    CrossRef

  14. 14
    Samuel Díaz-Insa, Carlos Vila, Caroline C. McGown, Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study, Current Medical Research and Opinion, 2011, 27, 3, 559

    CrossRef

  15. You have free access to this content15
    Peer C. Tfelt-Hansen, Peter J. Koehler, One Hundred Years of Migraine Research: Major Clinical and Scientific Observations From 1910 to 2010, Headache: The Journal of Head and Face Pain, 2011, 51, 5
  16. 16
    Tony W. Ho, Lars Edvinsson, Peter J. Goadsby, CGRP and its receptors provide new insights into migraine pathophysiology, Nature Reviews Neurology, 2010, 6, 10, 573

    CrossRef

  17. 17
    Peter J Goadsby, Till Sprenger, Current practice and future directions in the prevention and acute management of migraine, The Lancet Neurology, 2010, 9, 3, 285

    CrossRef

  18. 18
    Peer Carsten Tfelt-Hansen, Does sumatriptan cross the blood–brain barrier in animals and man?, The Journal of Headache and Pain, 2010, 11, 1, 5

    CrossRef

  19. 19
    Peter J. Goadsby, Headache, Neurotherapeutics, 2010, 7, 2, 149

    CrossRef

  20. 20
    Massimo Leone, Carlos Vila, Caroline McGown, Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study, Expert Review of Neurotherapeutics, 2010, 10, 9, 1399

    CrossRef

  21. You have free access to this content21
    Marcelo E. Bigal, Michel Ferrari, Stephen D. Silberstein, Richard B. Lipton, Peter J. Goadsby, Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science, Headache: The Journal of Head and Face Pain, 2009, 49,
  22. 22
    Carl Dahlöf, Hans-Christoph Diener, Migraine: an endemic disease inside the blood–brain barrier, Future Neurology, 2009, 4, 4, 405

    CrossRef

  23. 23
    Jes Olesen, Rami Burstein, Messoud Ashina, Peer Tfelt-Hansen, Origin of pain in migraine: evidence for peripheral sensitisation, The Lancet Neurology, 2009, 8, 7, 679

    CrossRef

  24. 24
    Peter J. Goadsby, Pathophysiology of Migraine, Neurologic Clinics, 2009, 27, 2, 335

    CrossRef

  25. 25
    N. M. Kushnir-Sukhov, E. Brittain, L. Scott, D. D. Metcalfe, Clinical correlates of blood serotonin levels in patients with mastocytosis, European Journal of Clinical Investigation, 2008, 38, 12
  26. 26
    PJ Koehler, PC Tfelt-Hansen, History of methysergide in migraine, Cephalalgia, 2008, 28, 11
  27. 27
    P. J. Goadsby, The vascular theory of migraine--a great story wrecked by the facts, Brain, 2008, 132, 1, 6

    CrossRef

  28. 28
    Marcela Romero-Reyes, Steven Graff-Radford, Is There Hope for Chronic Pain and Headache?, Headache: The Journal of Head and Face Pain, 2007, 47, 8
  29. 29
    Avi Ashkenazi, Stephen Silberstein, Menstrual migraine: a review of hormonal causes, prophylaxis and treatment, Expert Opinion on Pharmacotherapy, 2007, 8, 11, 1605

    CrossRef

  30. 30
    Richard Hargreaves, New Migraine and Pain Research, Headache: The Journal of Head and Face Pain, 2007, 47,
  31. 31
    Ernest A. Jennings, Hyun-jung Cho, Peripheral sensitization in migraine—role for P2X purinergic receptors in the dura–vascular sensory pathway, Drug Development Research, 2007, 68, 6
  32. 32
    ANTHONY J. TOMASSONI, CARL A. GERMANN, Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 2007,

    CrossRef

  33. 33
    Peter J Goadsby, Migraine: emerging treatment options for preventive and acute attack therapy, Expert Opinion on Emerging Drugs, 2006, 11, 3, 419

    CrossRef

  34. 34
    R Shrivastava, J C Pechadre, G W John, Tanacetum parthenium and Salix??alba??(Mig-RL??) Combination in??Migraine Prophylaxis, Clinical Drug Investigation, 2006, 26, 5, 287

    CrossRef

  35. 35
    Peter J. Goadsby, Roger Yates, Zolmitriptan Intranasal: A Review of the Pharmacokinetics and Clinical Efficacy, Headache: The Journal of Head and Face Pain, 2006, 46, 1
  36. 36
    A.N. Rich, J.L. Bradshaw, J.B. Mattingley, A systematic, large-scale study of synaesthesia: implications for the role of early experience in lexical-colour associations, Cognition, 2005, 98, 1, 53

    CrossRef

  37. 37
    Peter J. Goadsby, Can we Develop Neurally Acting Drugs for the Treatment of Migraine?, Nature Reviews Drug Discovery, 2005, 4, 9, 741

    CrossRef

  38. 38
    Julio Pascual, Pedro Muñoz, Correlation Between Lipophilicity and Triptan Outcomes, Headache: The Journal of Head and Face Pain, 2005, 45, 1
  39. 39
    Elliot Shevel, Craniomandibular muscles, intraoral orthoses and migraine, Expert Review of Neurotherapeutics, 2005, 5, 3, 371

    CrossRef

  40. 40
    C. Vollono, A. Capuano, D. Mei, D. Ferraro, L. Pierguidi, M. Evangelista, G. Di Trapani, Multiple attack study on the available triptans in Italy versus placebo, European Journal of Neurology, 2005, 12, 7
  41. 41
    Geoffrey A. Lambert, Preclinical Neuropharmacology of Naratriptan, CNS Drug Reviews, 2005, 11, 3
  42. 42
    Gretchen E. Tietjen, Kathy Athanas, Christine Utley, Nabeel A. Herial, Sadik A. Khuder, The Combination of Naratriptan and Prochlorperazine in Migraine Treatment, Headache: The Journal of Head and Face Pain, 2005, 45, 6
  43. 43
    JR Baldwin, JC Fleishaker, NE Azie, BJ Carel, A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults, Cephalalgia, 2004, 24, 4
  44. 44
    Peter J. Goadsby, Post-triptan era for the treatment of acute migraine, Current Pain and Headache Reports, 2004, 8, 5, 393

    CrossRef

  45. 45
    Ninan T. Mathew, Early Intervention With Almotriptan Improves Sustained Pain-free Response in Acute Migraine, Headache: The Journal of Head and Face Pain, 2003, 43, 10
  46. 46
    P.J Goadsby, J.D Classey, Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input, Neuroscience, 2003, 122, 2, 491

    CrossRef

  47. 47
    Lauren Kondev, Anna Minster, Headache and facial pain in children and adolescents, Otolaryngologic Clinics of North America, 2003, 36, 6, 1153

    CrossRef

  48. 48
    AJ Dowson, H Massiou, JM Laı´nez, X Cabarrocas, Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial, Cephalalgia, 2002, 22, 6
  49. 49
    Carl G.H. Dahlöf, David Dodick, Andrew J. Dowson, Julio Pascual, How Does Almotriptan Compare With Other Triptans? A Review of Data From Placebo-Controlled Clinical Trials, Headache: The Journal of Head and Face Pain, 2002, 42, 2
  50. 50
    Sylvia Lucas, Initial abortive treatments for migraine headache, Current Treatment Options in Neurology, 2002, 4, 5, 343

    CrossRef

  51. 51
    Alastair J.J. Wood, Peter J. Goadsby, Richard B. Lipton, Michel D. Ferrari, Migraine — Current Understanding and Treatment, New England Journal of Medicine, 2002, 346, 4, 257

    CrossRef

  52. 52
    PJ Goadsby, Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine, Cephalalgia, 2002, 22, 2
  53. 53
    MD Ferrari, PJ Goadsby, KI Roon, RB Lipton, Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials, Cephalalgia, 2002, 22, 8
  54. 54
    Reijo Salonen, Andrew Scott, Triptans: Do they differ?, Current Pain and Headache Reports, 2002, 6, 2, 133

    CrossRef

  55. 55
    Nabih M. Ramadan, Acute Treatments: Some Blind Alleys, Current Medical Research and Opinion, 2001, 17, s1, s71

    CrossRef

  56. 56
    Joseph C. Fleishaker, Kristi K. Ryan, Josep M. Jansat, Barabara J. Carel, David J. A. Bell, Moira T. Burke, Nkechi E. Azie, Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans, British Journal of Clinical Pharmacology, 2001, 51, 5
  57. 57
    Jc Fleishaker, Ta Sisson, Bj Carel, Ne Azie, Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers, Cephalalgia, 2001, 21, 1
  58. 58
    Joel R. Saper, Alvin E. Lake, Stewart J. Tepper, Nefazodone for Chronic Daily Headache Prophylaxis: An Open-Label Study, Headache: The Journal of Head and Face Pain, 2001, 41, 5
  59. 59
    Michel D Ferrari, Krista I Roon, Richard B Lipton, Peter J Goadsby, Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials, The Lancet, 2001, 358, 9294, 1668

    CrossRef

  60. 60
    Carl G. H. Dahlöf, Sumatriptan: Pharmacological Basis and Clinical Results, Current Medical Research and Opinion, 2001, 17, s1, s35

    CrossRef

  61. 61
    Roel A Ophoff, Arn M.J.M van den Maagdenberg, Krista I Roon, Michel D Ferrari, Rune R Frants, The impact of pharmacogenetics for migraine, European Journal of Pharmacology, 2001, 413, 1, 1

    CrossRef

  62. 62
    Karthick Vishwanathan, Michael G. Bartlett, James T. Stewart, Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry, Rapid Communications in Mass Spectrometry, 2000, 14, 3
  63. 63
    Peter J. Goadsby, Reply to Spierings, Headache: The Journal of Head and Face Pain, 2000, 40, 9
  64. 64
    Peter J Goadsby, The pharmacology of headache, Progress in Neurobiology, 2000, 62, 5, 509

    CrossRef

  65. 65
    Kma Welch, Nt Mathew, P Stone, W Rosamond, J Saiers, D Gutterman, Tolerability of sumatriptan: clinical trials and post-marketing experience, Cephalalgia, 2000, 20, 8, 687

    CrossRef

  66. 66
    Kma Welch, Nt Mathew, P Stone, W Rosamond, J Saiers, D Gutterman, Tolerability of sumatriptan: clinical trials and post-marketing experience, Cephalalgia, 2000, 20, 8
  67. 67
    Lars Edvinsson, Sergio Gulbenkian, Carla P Barroso, Manuel Cunha e Sá, Julia M Polak, Anders Mortensen, Linda Jørgensen, Inger Jansen-Olesen, Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility, Peptides, 1998, 19, 7, 1213

    CrossRef

  68. 68
    B.D Duléry, M.A Petty, J Schoun, M David, N.D Huebert, A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit, Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 7, 1009

    CrossRef

  69. 69
    Mary C. Wolff, Mark J. Benvenga, David O. Calligaro, Ray W. Fuller, Jaswant S. Gidda, Susan Hemrick-Luecke, James B. Lucot, David L. Nelson, Carl D. Overshiner, J. David Leander, Pharmacological profile of LY301317, a potent and selective 5-HT1A agonist, Drug Development Research, 1997, 40, 1
  70. 70
    Jim J Hagan, Paula D Slade, Laramie Gaster, Phillip Jeffrey, Jonathan P Hatcher, D.N Middlemiss, Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig, European Journal of Pharmacology, 1997, 331, 2-3, 169

    CrossRef

  71. 71
    Margaret A Petty, Jack Elands, Michael P Johnson, Matthew D Linnik, Edith Hamel, Michael A Moskowitz, Win Sok Lee, Deborah R McCarty, Marcel Hibert, Bruce M Baron, The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine, European Journal of Pharmacology, 1997, 336, 2-3, 127

    CrossRef

  72. 72
    R. E. WOJNAR-HORTON, L. P. HACKETT, P. YAPP, L. J. DUSCI, M. PAECH, K. F. ILETT, Distribution and excretion of sumatriptan in human milk, British Journal of Clinical Pharmacology, 1996, 41, 3
  73. 73
    M. Sandrini, G. Vitale, A.V. Vergoni, A. Ottani, A. Bertolini, Effect of acute and chronic treatment with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the rat brain, Life Sciences, 1996, 58, 18, 1551

    CrossRef

  74. 74
    Geoffrey Lambert, Jan Michalicek, Effect of antimigraine drugs on dural blood flows and resistances and the responses to trigeminal stimulation, European Journal of Pharmacology, 1996, 311, 2-3, 141

    CrossRef

  75. 75
    Moira Dunne, Peter Andrew, Fully automated assay for the determination of sumatriptan in human serum using solid-phase extraction and high-performance liquid chromatography with electrochemical detection, Journal of Pharmaceutical and Biomedical Analysis, 1996, 14, 6, 721

    CrossRef

  76. 76
    Raphaela Verheggen, Stefan Freudenthaler, Frauke Meyer-Dulheuer, Alberto J. Kaumann, Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs, British Journal of Pharmacology, 1996, 117, 2
  77. 77
    J. Lincoln, Innervation of cerebral arteries by nerves containing 5-hydroxytryptamine and noradrenaline, Pharmacology & Therapeutics, 1995, 68, 3, 473

    CrossRef

  78. 78
    Rachel A. Spokes, Vicki C. Middlefell, Simultaneous measurement of plasma protein extravasation and carotid vascular resistance in the rat, European Journal of Pharmacology, 1995, 281, 1, 75

    CrossRef

  79. 79
    J.M. Elliott, T.P. Flanigan, N.R. Newberry, T. Zetterström, R.A. Leslie, 5-HT receptor sub-types: Aspects of their regulation and function, Neurochemistry International, 1994, 25, 6, 537

    CrossRef

  80. 80
    Celestine T. O'Shaughnessy, Helen E. Connor, Activation of sensory nerves in guinea-pig isolated basilar artery by nicotine: evidence for inhibition of trigeminal sensory neurotransmission by sumatriptan, European Journal of Pharmacology, 1994, 259, 1, 37

    CrossRef

  81. 81
    Sara L. Shepheard, David Jordan, Andrew G. Ramage, Comparison of the effects of IVth ventricular administration of some tryptamine analogues with those of 8-OH-DPAT on autonomic outflow in the anaesthetized cat, British Journal of Pharmacology, 1994, 111, 2
  82. 82
    Michael J. Garvey, Mary Noel, Association of levels of N-acetyl-beta-glucosaminidase with specific psychiatric symptoms in bipolar patients, Psychiatry Research, 1993, 47, 2, 129

    CrossRef

  83. 83
    Kathleen J. Bamforth, Alwen L. Jones, Richard C. Roberts, Michael W.H. Coughtrie, Common food additives are potent inhibitors of human liver 17α-ethinyloestradiol and dopamine sulphotransferases, Biochemical Pharmacology, 1993, 46, 10, 1713

    CrossRef

  84. 84
    Peter D. Andrew, Helen L. Birch, Deborah A. Phillpot, Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection, Journal of Pharmaceutical Sciences, 1993, 82, 1
  85. 85
    Masahiro Kobari, Yasuo Fukuuchi, Minora Tomita, Norio Tanahashi, Shizuko Konno, Hidetaka Takeda, Effects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat, British Journal of Pharmacology, 1993, 110, 4
  86. 86
    Holger Kaube, Karen L. Hoskin, Peter J. Goadsby, Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption, British Journal of Pharmacology, 1993, 109, 3
  87. 87
    C.T. O'Shaughnessy, G.J. Waldron, H.E. Connor, Lack of effect of sumatriptan and UK-14,304 on capsaicin-induced relaxation of guinea-pig isolated basilar artery, British Journal of Pharmacology, 1993, 108, 1
  88. 88
    POSTER COMMUNICATIONS, British Journal of Pharmacology, 1993, 108, S1
  89. 89
    Michael I. Stanley, Richard J. Berger, Mario Zuccarello, Jeffrey T. Keller, Serotonin (5-HT) fibers of the rat dura mater: 5-HT-positive, but not authentic serotoninergic, tryptophan hydroxylase-like fibers, Neuroscience Letters, 1993, 162, 1-2, 89

    CrossRef

  90. 90
    E. Stewart Johnson, 1993,

    CrossRef

  91. 91
    M. Gabriella Buzzi, Violetta Dimitriadou, Theoharis C. Theoharides, Michael A. Moskowitz, 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation, Brain Research, 1992, 583, 1-2, 137

    CrossRef

  92. 92
    Michel D. Ferrari, Pramod R.S. Saxena, Clinical effects and mechanism of action of sumatriptan in migraine, Clinical Neurology and Neurosurgery, 1992, 94, 73

    CrossRef

  93. 93
    Marinus O. Boer, Judith A.E. Somers, Pramod R. Saxena, Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig, British Journal of Pharmacology, 1992, 107, 2
  94. 94
    Andrew A. Parsons, 5-HT receptors in human and animal cerebrovasculature, Trends in Pharmacological Sciences, 1991, 12, 310

    CrossRef

  95. 95
    P. P. A. Humphrey, 5-Hydroxytryptamine and the pathophysiology of migraine, Journal of Neurology, 1991, 238, S1, S38

    CrossRef

  96. 96
    Andrew A. Parsons, Manijeh Motevalian, Eric T. Whalley, Contractile effects of 8-hydroxy-2-(di-n-propylamino) tetralin and flesinoxan in human isolated basilar artery, European Journal of Pharmacology, 1991, 202, 1, 17

    CrossRef

  97. 97
    Patrick P.A. Humphrey, Wasyl Feniuk, Mode of action of the anti-migraine drug sumatriptan, Trends in Pharmacological Sciences, 1991, 12, 444

    CrossRef